Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22734411 | 1.00 | ITGB1 (0.41) | ITGB1ITGA4TLR7SMN1; SMN2LMNA | |
| SCHEMBL30810218 | 1.00 | ITGB1 (0.41) | ITGB1ITGA4TLR7SMN1; SMN2LMNA | |
| SCHEMBL30810166 | 1.00 | ITGB1 (0.41) | ITGB1ITGA4TLR7SMN1; SMN2LMNA | |
| SCHEMBL22734446 | 1.00 | ITGB1 (0.41) | ITGB1ITGA4TLR7SMN1; SMN2LMNA | |
| SCHEMBL22734402 | 1.00 | ITGB1 (0.41) | ITGB1ITGA4TLR7SMN1; SMN2LMNA | |
| SCHEMBL30810203 | 1.00 | ITGB1 (0.41) | ITGB1ITGA4TLR7SMN1; SMN2LMNA | |
| SCHEMBL22734400 | 1.00 | ITGB1 (0.41) | ITGB1ITGA4TLR7SMN1; SMN2LMNA | |
| SCHEMBL22734412 | 1.00 | ITGB1 (0.41) | ITGB1ITGA4TLR7SMN1; SMN2LMNA | |
| SCHEMBL22734470 | 0.97 | ITGB1 (0.39) | ITGB1ITGA4TLR7SMN1; SMN2LMNA | |
| SCHEMBL22734471 | 0.97 | ITGB1 (0.39) | ITGB1ITGA4TLR7SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3759107-B1 | SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS WITH AN N-1 BRANCHED GROUP | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-111788202-B | Substituted imidazo [4,5-c ] quinoline compounds with N-1 branched groups | 3M创新有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-11370788-B2 | Substituted imidazo[4,5-c]quinoline compounds with an N-1 branched group | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2022-06-28 | — | — | US | disclosed |
| US-20200385379-A1 | SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS WITH AN N-1 BRANCHED GROUP | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370788-B2 | Substituted imidazo[4,5-c]quinoline compounds with an N-1 branched group | IFNG, IFNAR1, IRF3 | ITGB1 1554/4885ITGA4 2176/4885TLR7 35/4885 |
| US-20200385379-A1 | SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS WITH AN N-1 BRANCHED GROUP | IFNG, IFNAR1, IRF3 | ITGB1 2908/4885ITGA4 2568/4885TLR7 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.